Document is current
Any future updates will be listed below
-
Authors
Zhang, Jianying https://orcid.org/0000-0001-8161-7536
Wang, He-Ling https://orcid.org/0000-0002-8920-1487
Lautrup, Sofie https://orcid.org/0000-0002-6632-7853
Nilsen, Hilde Loge https://orcid.org/0000-0003-2115-2663
Treebak, Jonas T. https://orcid.org/0000-0003-1488-7012
Watne, Leiv Otto https://orcid.org/0000-0003-0441-6700
Selbæk, Geir https://orcid.org/0000-0001-6511-8219
Wu, Lindsay E. https://orcid.org/0000-0002-1599-7574
Omland, Torbjørn https://orcid.org/0000-0002-6452-0369
Pirinen, Eija https://orcid.org/0000-0003-1495-3972
Cheung, Tin Cho
Wang, Jun
Ziegler, Mathias https://orcid.org/0000-0001-6961-2396
Tysnes, Ole-Bjørn https://orcid.org/0000-0002-7230-6426
Zapata-Pérez, Rubén https://orcid.org/0000-0003-4432-9652
Bruzzone, Santina https://orcid.org/0000-0003-2034-3716
Canto, Carles https://orcid.org/0000-0002-5167-7922
Deleidi, Michela https://orcid.org/0000-0003-0357-0124
Janssens, Georges E. https://orcid.org/0000-0003-2104-8145
Houtkooper, Riekelt H. https://orcid.org/0000-0001-9961-0842
Scheibye-Knudsen, Morten https://orcid.org/0000-0002-6637-1280
Koshizaka, Masaya https://orcid.org/0000-0001-7374-9993
Yokote, Koutaro https://orcid.org/0000-0003-3033-4813
Verdin, Eric https://orcid.org/0000-0003-3703-3183
Bohr, Vilhelm A. https://orcid.org/0000-0003-4823-6429
Tzoulis, Charalampos https://orcid.org/0000-0003-0341-5191
Sinclair, David A. https://orcid.org/0000-0002-9936-436X
Fang, Evandro Fei https://orcid.org/0000-0003-0355-7202
- License Information
-
More Information
Article History
Received: 27 August 2024
Accepted: 23 July 2025
First Online: 9 September 2025
Competing interests
: E.F.F. is a co-owner of Fang-S Consultation AS (organization no. 931 410 717) and NO-Age AS (organization no. 933 219 127); has a material transfer agreement with LMITO Therapeutics (South Korea), a CRADA arrangement with ChromaDex (USA), a commercialization agreement with Molecule AG/VITADAO and material transfer agreements with GeneHarbor (Hong Kong) Biotechnologies Limited and Hong Kong Longevity Science Laboratory (Hong Kong); is a consultant for MindRank AI (China), NYO3 (Norway), AgeLab (Vitality Nordic AS, Norway) and Hong Kong Longevity Science Laboratory (Hong Kong). H.L.N. is an owner of NilsenRepairAge Consulting (organization no. 932146797) and NO-Age AS (organization no. 933219127); has a CRADA arrangement with ChromaDex (USA) and is a consultant for Ambr Institute (Norway), MitoTerapeutics (Norway) and AgeLab (Vitality Nordic AS, Norway). C.T. is listed as inventor on international patent applications relating to the use of NR as a treatment for PD. These patents have been filed by the Technology Transfer Office ‘Vestlandets Innovasjonsselskap As (VIS)’ on behalf of Haukeland University Hospital, Bergen, Norway (PCT/EP2022/067408, PCT/EP2022/067412 and PCT/EP2023/060962). G.S. has received honoraria for giving lectures at symposia sponsored by Eisai and Eli Lilly and has participated at advisory board meetings for Eisia, Roche and Eli Lilly concerning the manufacture of disease-modifying therapies for AD. T.O. has received institutional research support from ChromaDex (USA). E.P. reports a relationship with ChromaDex that includes speaking and lecture fees. M.Z. is chief scientist at Blue Helix Health AS. K.Y. and M.K. have received research support from ChromaDex (USA) via their institution. V.B. is a member of the Chromadex Scientific Advisory Board. T.C.C. and J.W. are inventors and consultants in the Hong Kong Longevity Science Laboratory. D.A.S. is a consultant, inventor, board member and, in some cases, an investor in Atai (2021–present) I; Galilei Biosciences SIRT6 activators (2014–present) F, I, E, A, B; InsideTracker (Segterra), Cambridge, MA I, A, IP (2011–present) B (2011–2017); Zymo Research Irvine, CA, molecular biology (2017–present) A; MetroBiotech, an EdenRoc company also known as Bauhaus; NAD boosters (2015–present) F, I, E, A, B (EdenRoc), IP; Life Biosciences Boston, and affiliates, Cantata Bio (formerly Dovetail Genomics and Arc Bio), Delavie Sciences (2017–present) F, I, E, A, B, IP; Levels (2021–present) E, A; Bold Capital (2021–present) E, A; Falcon Edge Capital (2021–present) E; AFAR (American Federation for Aging Research) B, A, F; Life Extension Advocacy Foundation (LEAF) A; Animal Biosciences (2017–present) I, E; Immetas (2018–present) F, I, E, A, B; Jumpstart Fertility, a Life Biosciences Company, F, I, E, A, B, IP; Fully Aligned Co, F, E, B, IP. F, founder; I, investor; E, equity; A, advisor/consultant; B, board of directors; IP, inventor on licensed patents; L, funding for laboratory (for further information about the affiliations of D.A.S., including those judged not relevant to this work, see ). L.E.W. is a scientific advisor and shareholder in Metro Biotech and Jumpstart Fertility. The other authors declare no competing interests.
